AlphAIAlphAI — Financial news for AI agents
tradingview.comOCT 131 min read$CODX

Co-Diagnostics Secures Up to $3.1M Convertible Financing; Sets ATM Sweep, Collateral and Registration Terms

Co-Diagnostics secured up to $3.1M in senior secured convertible notes from J.J. Astor & Co., with $2.1M initially funded. The notes have a 1.35x factor, 30 weekly installments, and are backed by a senior-priority lien and subsidiary guarantees. The company also agreed to an ATM proceeds waterfall and a registration rights deal for resale of conversion-related shares. Maxim Group was engaged as placement agent.

Original reporting
tradingview.com
Published Oct 13, 2026, 10:13 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 13, 2026, 10:32 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Co-Diagnostics Secures Up to $3.1M Convertible Financing; Sets ATM Sweep, Collateral and Registration Terms — source image
Source · tradingview.com
Decision brief

The 30-second read

$CODXBearishLow
01

Why it matters

The financing adds senior debt and potential equity conversion, which may dilute existing shareholders and increase leverage.

02

Market read

A micro‑cap biotech raises modest convertible financing, likely causing short‑term price pressure.

03

What to watch

Details on use of proceeds and conversion terms are not disclosed, which could affect the actual impact.

Relevance 5/10Novelty 5/10Timing: post‑announcement today

Background

Co-Diagnostics is a clinical diagnostics company seeking liquidity through convertible debt.

Company-level read

Ticker impact

$CODXBearishMedium confidence
Context

Co-Diagnostics announced a senior secured convertible financing of up to $3.1M, including $2.1M funded and an option for $1M more.

Expected impact

likely pressure as the market prices in dilution and added leverage

Evidence & confidence

Convertible financing at a modest size for a micro‑cap suggests short‑term share‑price downside due to dilution risk.

Market effects

Sector

Limited impact; similar biotech financing trends may be noted by sector investors.

Regional

US micro‑cap biotech space sees modest funding activity.

Global

Low; the financing is company‑specific and not macro‑driven.

Counterpoint

What could challenge this read

If the capital is used for a breakthrough product, the dilution could be offset by future upside.

Key entities

  • Financier
    J.J. Astor & Co.

    Lead arranger of the convertible loan.

  • Placement Agent
    Maxim Group

    Handles ATM proceeds waterfall and placement.

Read at source← All news

Related articles

AUG 13
$CODXMed

Co-Diagnostics Reports Second Quarter 2026 Financial Results

Co-Diagnostics (Nasdaq: CODX) reported Q2 2026 results for the quarter ended June 30, 2026. Revenue was $0.17M vs $0.16M a year earlier. Operating loss was $6.2M, net loss $6.3M ($1.46/share). Cash was $3.6M. The company said it completed studies and submitted a 510(k) for its Flu A/B and RSV multiplex test, and raised $3.0M via private placement.

prnewswire.com6 min
AUG 13
$CODXMed

Co-Diagnostics Reports Second Quarter 2026 Financial Results

Co-Diagnostics, Inc. (CODX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Co-Diagnostics Reports Second Quarter 2026 Financial Results Advancing Commercialization Through FDA Submission, Global Clinical Progress and Manufacturing Expansion Strengthening Integrated Co-Dx PCR Platform Through Scientific Innovation, Cloud Connectivity and AI-

SEC EDGAR 8-K6 min
AUG 13
$CODXMed

Co-Diagnostics submits flu/RSV test after study of more than 1,400 patients

Co-Diagnostics (Nasdaq: CODX) reported Q2 2026 revenue of $0.17 million, up from $0.16 million a year earlier, with a net loss of $6.3 million ($1.46/share) versus a $7.7 million loss in Q2 2025. Cash fell to $3.6 million from $11.9 million. The company said it completed studies for an FDA 510(k) and CLIA waiver for its Flu A/B & RSV PCR test and raised $3.0 million in a private placement.

stocktitan.net6 min
AUG 6
$CODXMed

Co-Diagnostics Submits FDA 510(k) Premarket Notification for Upper Respiratory Point-of-Care Test

Co-Diagnostics (Nasdaq: CODX) said it submitted a Dual 510(k) premarket notification with a concurrent CLIA Waiver by Application to the FDA for its Co-Dx PCR Flu A/B & RSV upper respiratory multiplex test on the Co-Dx PCR Pro instrument. The filing follows clinical studies of 1,400 symptomatic patients and analytical work across 27 studies and 10,000+ PCR runs. If granted, the CLIA waiver would enable decentralized point-of-care use; the platform is not yet for sale.

prnewswire.com2 min
JUL 1
$CODXMed

EXCLUSIVE: Co-Diagnostics Reaches Regulatory Milestone for PCR Respiratory Test Platform - Co-Diagnostics

Co-Diagnostics (NASDAQ:CODX) said it completed clinical and analytical performance studies for its Co-Dx PCR Flu A/B & RSV multiplex test on the Co-Dx PCR Pro instrument. The company plans to include the results in its FDA submission package for a Dual 510(k) and CLIA Waiver by Application targeted for Q3 2026. Shares were down 0.65% premarket to $3.08.

benzinga.com4 min
MAY 29
$SPRCMedAI 8/10

Top Biotech Gainers: SPRC Deal Gets Nod, CODX Rallies, OTLK, AKTX, FTRE Drawing Investor Interest

SciSparc (SPRC) shares rose ~140% after its TSX Venture subsidiary received conditional approval to buy ~54% of private Israeli CliniQuantum for 56.6M NeuroThera shares (~$9.46M). Co-Diagnostics (CODX) gained ~53% for a third day amid Ebola PCR assay progress. Akari (AKTX) jumped ~38% on ASCO abstract acceptance and new KRAS-mutant synergy data; Outlook (OTLK) rose ~26% ahead of a June FDA resubmission.

rttnews.com6 min